贝马里妥珠单抗，Bemarituzumab，anti-FGFR2 antibody 抗体

Tags:Bemarituzumab 代理商,Bemarituzumab 价格,Bemarituzumab 供应商， Bemarituzumab supplier,Bemarituzumab purchase,Bemarituzumab 购买,Bemarituzumab 销售

Description

Bemarituzumab (bema), a first-in-class humanized IgG1 monoclonal antibody, selectively binds to 2b Isoform of thefibroblast growth factor receptor (FGFR2b). Bemarituzumab (FPA144) is a first-in-class humanized immunoglobulin G1 monoclonal antibody specific to the splice-variant FGFR2b that inhibits binding of the ligands FGF7, FGF10, and FGF22. Specifically, bemarituzumab does not inhibit binding of FGF23, the ligand responsible for phosphate and vitamin D metabolism, thereby potentially avoiding the risk of hyperphosphatemia associated with pan-FGFR tyrosine kinase inhibitors. Bemarituzumab is also glycoengineered for increased affinity for the human Fc gamma RIIIA receptor expressed on natural killer cells, enabling enhanced antibody-dependent cellmediated cytotoxicity.

Catalog No.

DHD47901

Host species

Humanized

Species reactivity

Human

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Concentration

1 mg/ml

Purity

>95%

Clonality

Monoclonal

Isotype

IgG1-kappa

Applications

Research Grade Biosimilar

Target

K-sam, KSAM, CD332, Keratinocyte growth factor receptor, Fibroblast growth factor receptor 2, FGFR-2, FGFR2, KGFR, BEK

Purification

Protein A or G purified from cell culture supernatant.

Endotoxin level

Please contact with the lab for this information.

Expression system

XtenCHO

Accession

P21802

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.

Alternative Names

FPA144 ,FPA-144, FPA114-A, CAS: 1952272-74-0

Note

For research use only. Not suitable for clinical or therapeutic use.